Navigation Links
Exelixis Announces Third Quarter 2007 Financial Results and Business Update
Date:11/5/2007

e sale of assets recognized in conjunction with our transaction with Agrigenetics Inc., a wholly-owned subsidiary of The Dow Chemical Company, which was accounted for as a sale of our plant trait business.

Cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. (a consolidated clinical development financing vehicle) and restricted cash and investments totaled $297.6 million at September 30, 2007, compared to $263.2 million at December 31, 2006.

Q3 2007 Business Highlights

* In mid-September, we submitted a data report for XL880 to our partner

GlaxoSmithKline (GSK), which had requested an accelerated review of

XL880. GSK has 90 days from the date of submission of the data report

for XL880 to determine whether it will select XL880 for further

clinical development and commercialization.

* We presented encouraging data from a phase 2 proof-of-concept trial of

XL647 as first-line therapy for non-small cell lung cancer (NSCLC) at

the IASLC World Conference on Lung Cancer in Seoul, South Korea. On

October 24, 2007, we presented updated data from this same trial at

the AACR-NCI-EORTC Conference, where investigators reported that over

68% of evaluable patients had a clinical benefit. Out of 34 evaluable

patients, there were 10 partial responses and 13 cases of stable

disease. Responses were observed in patients with and without

activating EGFR mutations, and the compound was generally well

tolerated.

* We retained the right to develop and commercialize XL647 after GSK

declined its option to further develop the compound. Having clarified

ownership of the compound, we have begun an aggressive development

program that calls for pivotal trials of XL647 to be initiated in the

first half of 2008.

* We ex
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... Naurex Inc., a biopharmaceutical company leveraging its ... the central nervous system, today announced that Norbert ... present at the 33 rd annual J.P. Morgan ... 3:00 p.m. PST on Tuesday, January 13, 2015, at ... Calif. About Naurex Inc. ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Funds ... ... (PHRI) has received $2.8 million in research funding from the National Cancer Institute (NCI) to ... Hawaii, for two more years. , , , , ,Since 2002, PHRI has participated in ...
... WILMINGTON, Delaware, September 1 According to a ... ( http://www.marketsandmarkets.com ), the total global,biomaterials market is expected ... CAGR of 15.0% from 2009 to 2014. The U.S. ... total revenues. The biomaterials market today has,already crossed $28 ...
... ... of Cleveland, now offers reverse total shoulder replacement surgery. This innovative procedure relieves pain ... individuals -- who are not candidates for traditional shoulder replacement -- had been told ... ...
Cached Biology Technology:Pacific Health Research Institute Awarded $2.8 Million in Research Funding 2Pacific Health Research Institute Awarded $2.8 Million in Research Funding 3Global Biomaterials Market Worth US$58.1 Billion by 2014 2Global Biomaterials Market Worth US$58.1 Billion by 2014 3Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 2Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 3Robert Zanotti, MD, Is First Lorain County, Ohio Orthopedic Surgeon to Perform Reverse Total Shoulder Replacement 4
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... SE, Harvard University, the Massachusetts Institute of Technology (MIT), ... a research initiative called the "North American Center for ... this initiative is to jointly develop new materials for ... cooperation is initially planned for five years, during which ...
... WINSTON-SALEM, N.C. , March 11, 2013  Wake ... developments related to its commercialization enterprise, Wake Forest ... Piedmont Triad Research Park.   Wake Forest ... and beyond the community and an analysis of ...
... the microbiology field has challenged all previous knowledge of ... out studying this phenomenon, suggesting that there is a ... Northeastern University Distinguished Professor in the Department of Biology ... standard thinking at the time was that the three ...
Cached Biology News:Renewed Harvard-BASF initiative to advance functional materials 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 4Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 5Study: Antibiotics are unique assassins 2
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
Anti-human VEGFR-2/KDR (Protein-A Purified) Polyclonal Antibody...
Mouse monoclonal antibody to Lats2....
Goat polyclonal to Lipocalin 2...
Biology Products: